AdipoGen Life Sciences


CHF 80.00
In stock
AG-MR-C0035-M0011 mgCHF 80.00
AG-MR-C0035-M0055 mgCHF 320.00
More Information
Product Details
Synonyms (2R)-2-[(6-{[(5-Methylthiophen-2-yl)methyl]amino}-9-propyl-9H-purin-2-yl)amino]butan-1-ol; Rx-ID: 23159892
Product Type Chemical


MW 374.5
CAS 1402821-41-3
Purity Chemicals ≥97% (NMR)
Appearance White to off-white solid.
Solubility Soluble in DMSO or ethanol.
Reconstitution Stock solutions can be made up to 10mM in DMSO.
Identity Determined by 1H-NMR.
Smiles CCCN1C=NC2=C(NCC3=CC=C(C)S3)N=C(N[C@H](CC)CO)N=C12
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Selective N- and P/Q-type Ca2+-channel agonist. These Ca2+-channels regulate transmitter release in synapses.
  • Potential lead compound for a variety of disorders that result in neuromuscular weakness.
Product References
  1. Synthesis and biological evaluation of a selective N- and P/Q-type Calcium channel agonist: M. Liang, et al.; ACS Med. Chem. Lett. 3, 985 (2012)
  2. New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases: T.B. Tarr, et al.; Ann. N. Y. Acad. Sci. 1275, 85 (2012)
  3. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome: T.B. Tarr, et al.; J. Neurosci. 33, 10559 (2013)
  4. Complete reversal of Lambert–Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist: T.B. Tarr, et al.; J. Physiol. 3687, 592 (2014)
  5. Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome: T.B. Tarr, et al.; Mol. Neurobiol. 52, 456 (2015)
  6. The Calcium Channel Subunit Alpha2delta2 Suppresses Axon Regeneration in the Adult CNS: A. Tedeschi, et al.; Neuron 92, 419 (2016)
  7. New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease: M. Wu, et al.; Neuropharmacology 131, 176 (2018)
  8. R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy: R. Tejero, et al.; iSci. 23, 100826 (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.